The aim of this study was to evaluate the clinical value of two plasma-circulating lncRNAs, MALAT1 and NEAT1, as predictive biomarkers for post-RT adverse effects in LC patients. This evidence concerns the gene MALAT1 and laryngotracheoesophageal cleft.